Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani

Vaccine

Volumn 21, Issue 11-12, 2003, Pages 1292-1299

  Sukumaran, Bindu ^a   Tewary, Poonam ^a   Saxena, Shailendra ^a   Madhubala, Rentala ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

DNA vaccine; LD1 locus; ORFF gene

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; LEISHMANIA VACCINE; MESSENGER RNA; ORFF ANTIGEN; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL STRAIN COS1; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; EUKARYOTE; EXPRESSION VECTOR; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIA DONOVANI; LEISHMANIASIS; MOLECULAR CLONING; MOUSE; NONHUMAN; PARASITE IMMUNITY; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMASTIGOTE; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; TH1 CELL; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CERCOPITHECUS AETHIOPS; COS CELLS; FEMALE; GENE EXPRESSION REGULATION; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-4; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LIVER; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; PLASMIDS; POLYMERASE CHAIN REACTION; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RNA, MESSENGER; SPLEEN; TH1 CELLS; TRANSFECTION; VACCINATION; VACCINES, DNA;

EID: 0037424132     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00352-3     Document Type: Article

References (37)

1. Bebars M.A., El Serougi A.O., Makled K.M.et al. An experimental vaccine providing heterologous protection for Leishmania species in murine model. J. Egypt. Soc. Parasitol. 30(1):2000;137-156.
2. Cox F.E. Designer vaccines for parasitic diseases. Int. J. Parasitol. 27(10):1997;1147-1157.
3. Gurunathan S., Sacks D.L., Brown D.R.et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with L. major. J. Exp. Med. 186(7):1997;1137-1147.
4. Melbi P.C., Ogden G.B., Flores H.A.et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68(10):2000;5102-5595.
5. Muyombwe A., Olivier M., Harvie P., Bergeron M.G., Ouellette M., Papadopoulou B. Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene. J. Infect. Dis. 177(1):1998;188-195.
6. Rafati S., Baba A.A., Bakhshayesh M., Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin. Exp. Immunol. 120(1):2000;134-138.
7. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model I: induction of protective immunity with a soluble extract of promastigotes. J. Immunol. 139(1):1987;221-227.
8. Solioz N., Blum-Tirouvanziam U., Jacquet R.et al. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine. 18(9/10):1999;850-859.
9. Abdelhak S., Louzir H., Timm J.et al. Recombinant BCG expressing the Leishmania surface antigen gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology. 141(Pt 7):1995;1585-1592.
10. Lodes M.J., Merlin G., deVos T.et al. Increased expression of LD1 genes transcribed by RNA polymerase I in Leishmania donovani as a result of duplication into the rRNA gene locus. Mol. Cell. Biol. 15(12):1995;6845-6853.
11. Mbati P.A., Anjili C.O., Lugalia R.et al. Experimental immunization against cutaneous leishmaniasis using Leishmania major subcellular fractions alone or in combination with Phlebotomus duboscqi gut antigens. East Afr. Med. J. 72(8):1995;519-522.
12. Tripp C.A., Myler P.J., Stuart K. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Mol. Biochem. Parasitol. 47(2):1991;151-156.
13. Webb J.R., Kaufmann D., Campos-Neto A., Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157(11):1996;5034-5041.
14. Xu D., McSorley S.J., Chatfield S.N., Dougan G., Liew F.Y. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium (Aro A-Aro D-). Immunology. 85(1):1995;1-7.
15. Fragaki K., Suffia I., Ferrua B., Rousseau D., Fichoux Le., Kubar J. Immunization with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine. 19(13/14):2001;1701-1709.
16. Walker P.S., Scharton-Kersten T., Rowton E.D.et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T-cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene Ther. 9(13):1998;1899-1907.
17. Campos-Neto A., Porrozzi R., Greeson K.et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and non-human primate models of the human disease. Infect. Immun. 69:2001;4103-4108.
18. Pardoll D.M., Beckerleg A.M. Exposing the Immunology of naked DNA vaccines. Immunity. 3:1995;165-169.
19. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finelman F.D., Murray H.W. Th1 and Th2 Cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1994;1058-1063.
20. Kaye P.M., Curry A.J., Blackwell J.M. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled of vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:1991;2763-2770.
21. Karp C.L., El-Safi S.H., Wynn T.A.et al. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-γ J. Clin. Invest. 91(4):1993;1644-1648.
22. Kemp M., Kurtzhals J.A., Bendtzen K.et al. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61:1993;1069-1073.
23. Ghosh A., Madhubala R., Myler P.J., Stuart K.D. Leishmania donovani: characterization and expression of ORFF, a gene amplified from the LD1 locus. Expt. Parasitol. 93:1999;225-234.
24. Lemley C., Yan S., Dole V.S.et al. The Leishmania donovani LD1 locus gene ORFG encodes a biopterin transporter (BT1). Mol. Biochem. Parasitol. 104(1):1999;93-105.
25. Myler P.J., Venkataraman G.M., Lodes M.J., Stuart K.D. A frequently amplified region in Leishmania contains a gene that is conserved in prokaryotes and eukaryotes. Gene. 148:1994;187-193.
26. Raj V.S., Ghosh A., Dole V.S., Madhubala R. Serodiagnosis of leishmaniasis with recombinant ORFF antigen. Am. J. Trop. Med. Hyg. 61(3):1999;482-487.
27. Tripp C.A., Wisdom W.A., Myler P.J., Stuart K. A multicopy, extrachromosomal DNA in Leishmania infantum contains two inverted repeats of the 27.5 kb LD1 sequence and encodes numerous transcripts. Mol. Biochem. Parasitol. 55:1992;39-50.
28. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., Stuart K.D. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine. 19:2001;423-430.
29. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. U.S.A. 76(9):1979;4350-4354.
30. Fisher RA, Yates F. Student's t-test of significance. In: Statistical tables for agricultural and other research workers. Edinburgh: Oliver and Boyd; 1957. p. 1024-9.
31. Ghosh A., Labrecque S., Matlashewski G. Protection against Lesihmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine. 19:2001;3169-3178.
32. Blackwell J.M., Roberts B., Alexander J. Response of BALB/c mice to leishmanial infection. Curr. Top Microbiol. Immunol. 122:1985;97-106.
33. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 168:1988;1675-1684.
34. Lehman J., Enssle K.H., Lehmann I., Emmendorfer A., Lohmann-Matthes M.L. The capacity to produce IFN-γ rather than the presence of IL-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J. Interferon. Cytokine Res. 20(1):2000;63-77.
35. Alarcon J.B., Waine G.W., McManus D.P. DNA vaccines: technology and applications as anti-parasite and anti-microbial agents. Advances Parasitol. 42:1999;343-410.
36. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Ann. Rev. Immunol. 15:1997;617-648.
37. Pearson R.D., Sousa A.Q. Clinical spectrum of leishmaniasis. Clin. Infect. Dis. 22(1):1996;1-13.